138 related articles for article (PubMed ID: 31597787)
1. Melanoleuconychia: A rare reversible entity.
Sidhu AS; Das L; Singh AS
Postgrad Med J; 2020 Mar; 96(1133):167. PubMed ID: 31597787
[No Abstract] [Full Text] [Related]
2. A patient with cancer and nail pigmentation.
Maiti A; Bhattacharya S
BMJ; 2016 May; 353():i2346. PubMed ID: 27142474
[No Abstract] [Full Text] [Related]
3. Muehrcke's lines on nails after cyclophosphamide/adriamycin/fluorouracil.
Gül U; Kiliç A
Ann Pharmacother; 2004 Jun; 38(6):1089-90. PubMed ID: 15122002
[No Abstract] [Full Text] [Related]
4. Chemotherapy-induced diffuse melanonychia.
Hsu KF; Yang MH; Yu JC
Acta Clin Belg; 2008; 63(6):427. PubMed ID: 19170363
[No Abstract] [Full Text] [Related]
5. Melanonychia induced by topical 5-fluorouracil.
Baran R; Laugier P
Br J Dermatol; 1985 May; 112(5):621-5. PubMed ID: 4005160
[TBL] [Abstract][Full Text] [Related]
6. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation.
Yorulmaz A; Dogan M; Artuz F; Zengin N
Cutan Ocul Toxicol; 2017 Jun; 36(2):135-139. PubMed ID: 27086693
[TBL] [Abstract][Full Text] [Related]
7. Motor dominant neuropathy induced by adjuvant therapy with adriamycin and cyclophosphamide followed by dose-dense paclitaxel in a breast cancer patient.
Hikino H; Kawashima M; Yamada T; Ozaki N
Int J Clin Oncol; 2006 Aug; 11(4):332-5. PubMed ID: 16937310
[TBL] [Abstract][Full Text] [Related]
8. Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel).
Ghetti E; Piraccini BM; Tosti A
J Eur Acad Dermatol Venereol; 2003 Jul; 17(4):459-60. PubMed ID: 12834462
[TBL] [Abstract][Full Text] [Related]
9. Nail alterations secondary to pactitaxel [corrected] therapy.
Almagro M; Pozo JD; Garcia J; Vasquez A; Fonseca E
Eur J Dermatol; 2000 Mar; 10(2):146-7. PubMed ID: 10694317
[TBL] [Abstract][Full Text] [Related]
10. The one-nail brown band: macro- and micro-morphology.
Poppe LM; Bröcker EB; Trautmann A
Acta Derm Venereol; 2013 Jul; 93(4):479-80. PubMed ID: 23138662
[No Abstract] [Full Text] [Related]
11. Vitiligo in the affected breast during neo-adjuvant chemotherapy for breast cancer.
Rao MV; Shayne M
Breast Cancer Res Treat; 2009 Sep; 117(1):197-8. PubMed ID: 18592371
[No Abstract] [Full Text] [Related]
12. Beau's lines.
Chang CC; Wu CC
QJM; 2013 Apr; 106(4):383. PubMed ID: 22408154
[No Abstract] [Full Text] [Related]
13. Drug-induced nail abnormalities.
Piraccini BM; Iorizzo M; Antonucci A; Tosti A
Expert Opin Drug Saf; 2004 Jan; 3(1):57-65. PubMed ID: 14680462
[TBL] [Abstract][Full Text] [Related]
14. Why adjuvant trastuzumab led to better outcomes in women with high-risk HER-2-positive breast cancer.
Altundag K; Baptista MZ
Breast J; 2006; 12(5):497-8. PubMed ID: 16958977
[No Abstract] [Full Text] [Related]
15. A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast Cancer.
Stoen E; Kabos P; Borden KC; Brown RJ; Borges VF; Diamond JR
Oncology (Williston Park); 2018 Jun; 32(6):298-302. PubMed ID: 29940061
[No Abstract] [Full Text] [Related]
16. Leukonychia from 2-ethyl-cyanoacrylate glue.
Ena P; Mazzarello V; Fenu G; Rubino C
Contact Dermatitis; 2000 Feb; 42(2):105-6. PubMed ID: 10703637
[No Abstract] [Full Text] [Related]
17. Yellow nail syndrome in rheumatoid arthritis: a drug-induced disease?
David-Vaudey E; Jamard B; Hermant C; Cantagrel A
Clin Rheumatol; 2004 Aug; 23(4):376-8. PubMed ID: 15293107
[No Abstract] [Full Text] [Related]
18. [Yellow nails].
Auvinet M; Dahan S; Dingremont C; Ollier S; Juchet H; Arlet P
Rev Med Interne; 1998 May; 19(5):353-4. PubMed ID: 9775172
[No Abstract] [Full Text] [Related]
19. Discoloration of the nails and early anemia after mitoxantrone, folinic acid and 5-fluorouracil.
Seminara P; Franchi F; Codacci-Pisanelli G; Aronne T; Abdolrahim zadeh S
Med Oncol Tumor Pharmacother; 1990; 7(4):291-2. PubMed ID: 2283895
[No Abstract] [Full Text] [Related]
20. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.
Kahan Z; Uhercsak G; Hajnal-Papp R; Boda K; Thurzo L
Oncology; 2005; 68(4-6):446-53. PubMed ID: 16020975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
